nevirapine [Ligand Id: 12676] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL57 (BIRG 0587, BIRG-0587, Nevirapina, Nevirapine, Nevirapine anhydrous, Nevirapine, anhydrous, Nevirapine teva, Nevirapinum anhydrous, NSC-641530, Viramune, Viramune xr)
  • Human immunodeficiency virus type 1 protease in Human immunodeficiency virus 1 [ChEMBL: CHEMBL243] [UniProtKB: Q72874]
There should be some charts here, you may need to enable JavaScript!
  • Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 [ChEMBL: CHEMBL247] [UniProtKB: Q72547]
There should be some charts here, you may need to enable JavaScript!
  • Human immunodeficiency virus type 2 pol protein in Human immunodeficiency virus 2 [ChEMBL: CHEMBL5074] [UniProtKB: P88142]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
Human immunodeficiency virus type 1 protease in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL243] [UniProtKB: Q72874]
ChEMBL Inhibition single mutant of HIV-1 RT (K103 N) B 4.24 pIC50 57900 nM IC50 J Med Chem (1993) 36: 1291-1294 [PMID:7683725]
ChEMBL Inhibition single mutant of HIV-1 RT (Y181C) B 4.95 pIC50 11300 nM IC50 J Med Chem (1993) 36: 1291-1294 [PMID:7683725]
ChEMBL Inhibition of HIV-1 RT using rC-dG as template B 7 pIC50 101 nM IC50 J Med Chem (1993) 36: 1291-1294 [PMID:7683725]
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL247] [UniProtKB: Q72547]
ChEMBL Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 Y181I mutant expressed in Escherichia coli JM109 B 4.44 pKi 36000 nM Ki J Med Chem (2009) 52: 1224-1228 [PMID:19170521]
ChEMBL Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y181I B 4.44 pKi 36000 nM Ki J Med Chem (2001) 44: 305-315 [PMID:11462972]
ChEMBL In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution Y181I B 4.44 pKi 36000 nM Ki J Med Chem (1999) 42: 4462-4470 [PMID:10543890]
ChEMBL Inhibition of HIV1 reverse transcriptase Y188L mutant B 4.74 pKi 18000 nM Ki J Med Chem (2007) 50: 5412-5424 [PMID:17910429]
ChEMBL In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution Y188L B 4.74 pKi 18000 nM Ki J Med Chem (1999) 42: 4462-4470 [PMID:10543890]
ChEMBL Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y188L B 4.74 pKi 18000 nM Ki J Med Chem (2001) 44: 305-315 [PMID:11462972]
ChEMBL Inhibition of HIV1 reverse transcriptase V106A mutant B 5 pKi 10000 nM Ki J Med Chem (2007) 50: 5412-5424 [PMID:17910429]
ChEMBL Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution V106A B 5 pKi 10000 nM Ki J Med Chem (2001) 44: 305-315 [PMID:11462972]
ChEMBL In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution V106A B 5 pKi 10000 nM Ki J Med Chem (1999) 42: 4462-4470 [PMID:10543890]
ChEMBL Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 L100I mutant expressed in Escherichia coli JM109 B 5.05 pKi 9000 nM Ki J Med Chem (2009) 52: 1224-1228 [PMID:19170521]
ChEMBL Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution L1001 B 5.05 pKi 9000 nM Ki J Med Chem (2001) 44: 305-315 [PMID:11462972]
ChEMBL Inhibition of HIV1 reverse transcriptase L100I mutant B 5.05 pKi 9000 nM Ki J Med Chem (2007) 50: 5412-5424 [PMID:17910429]
ChEMBL In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution L100I B 5.05 pKi 9000 nM Ki J Med Chem (1999) 42: 4462-4470 [PMID:10543890]
ChEMBL Non-competitive inhibition of wild type HIV1 reverse transcriptase p66/p51 after 30 mins by liquid scintillation counting B 5.14 pKi 7200 nM Ki Bioorg Med Chem (2013) 21: 1150-1158 [PMID:23357038]
ChEMBL Inhibition of HIV1 reverse transcriptase K103N mutant B 5.15 pKi 7000 nM Ki J Med Chem (2007) 50: 5412-5424 [PMID:17910429]
ChEMBL In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution K103N B 5.15 pKi 7000 nM Ki J Med Chem (1999) 42: 4462-4470 [PMID:10543890]
ChEMBL Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 K103N mutant expressed in Escherichia coli JM109 B 5.15 pKi 7000 nM Ki J Med Chem (2009) 52: 1224-1228 [PMID:19170521]
ChEMBL Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution K103N B 5.15 pKi 7000 nM Ki J Med Chem (2001) 44: 305-315 [PMID:11462972]
ChEMBL Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA-dNTP ternary complex expressed in Escherichia coli BL21 B 5.3 pKi 5000 nM Ki J Med Chem (2009) 52: 840-851 [PMID:19140683]
ChEMBL Inhibition of HIV1 recombinant free reverse transcriptase K103N mutant expressed in Escherichia coli BL21 B 5.4 pKi 4000 nM Ki J Med Chem (2009) 52: 840-851 [PMID:19140683]
ChEMBL Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA binary complex expressed in Escherichia coli BL21 B 5.4 pKi 4000 nM Ki J Med Chem (2009) 52: 840-851 [PMID:19140683]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase-DNA binary complex B 6.3 pKi 500 nM Ki J Med Chem (2009) 52: 840-851 [PMID:19140683]
ChEMBL Inhibition of HIV-1 wild-type RT B 6.4 pKi 400 nM Ki J Med Chem (2001) 44: 305-315 [PMID:11462972]
ChEMBL Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 expressed in Escherichia coli JM109 B 6.4 pKi 400 nM Ki J Med Chem (2009) 52: 1224-1228 [PMID:19170521]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase-DNA-dNTP ternary complex B 6.4 pKi 400 nM Ki J Med Chem (2009) 52: 840-851 [PMID:19140683]
ChEMBL Inhibition of wild type HIV1 free reverse transcriptase B 6.4 pKi 400 nM Ki J Med Chem (2009) 52: 840-851 [PMID:19140683]
ChEMBL Inhibition of wild type HIV1 3B reverse transcriptase B 6.4 pKi 400 nM Ki J Med Chem (2007) 50: 5412-5424 [PMID:17910429]
ChEMBL In vitro inhibitory activity against HIV-1 wild type reverse transcriptase (RT) B 6.4 pKi 400 nM Ki J Med Chem (1999) 42: 4462-4470 [PMID:10543890]
ChEMBL Inhibition of HIV1 reverse transcriptase V179D mutant B 6.52 pKi 300 nM Ki J Med Chem (2007) 50: 5412-5424 [PMID:17910429]
ChEMBL Inhibitory activity against non-nucleoside reverse transcriptase inhibitors (NNRTI) -resistant HIV-1 strain A17 with a Y181C mutation in RT (reverse transcriptase) B 4 pIC50 >100000 nM IC50 Bioorg Med Chem Lett (2001) 11: 523-528 [PMID:11229762]
ChEMBL Inhibition of DNA dependent DNA polymerase activity of HIV1 reverse transcriptase Y181C mutant expressed in Escherichia coli BL21 B 4 pIC50 100000 nM IC50 J Med Chem (2008) 51: 5702-5713 [PMID:18800765]
ChEMBL Inhibitory activity against non-nucleoside reverse transcriptase inhibitors (NNRTI) -resistant HIV-1 strain A17 variant with Y181C plus K103N mutations in RT (reverse transcriptase) B 4 pIC50 >100000 nM IC50 Bioorg Med Chem Lett (2001) 11: 523-528 [PMID:11229762]
ChEMBL Concentration required for 50% inhibition of human immunodeficiency virus type 1 reverse transcriptase Ile100 B 4 pIC50 >100000 nM IC50 J Med Chem (2004) 47: 5912-5922 [PMID:15537346]
ChEMBL Fold increase in inhibitory concentration against HIV 1 reverse transcriptase mutant type Ile100 over wild type HIV 1 reverse transcriptase B 4 pIC50 >100000 nM IC50 J Med Chem (2004) 47: 5912-5922 [PMID:15537346]
ChEMBL Concentration required for 50% inhibition of human immunodeficiency virus type 1 reverse transcriptase mutant type Cys181 B 4 pIC50 >100000 nM IC50 J Med Chem (2004) 47: 5912-5922 [PMID:15537346]
ChEMBL Inhibition of HIV1 reverse transcriptase K103N mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis B 4.17 pIC50 67600 nM IC50 Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311]
ChEMBL Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay B 4.17 pIC50 >67000 nM IC50 Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127]
ChEMBL Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay B 4.17 pIC50 >67000 nM IC50 Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127]
ChEMBL In vitro inhibition of mutant Y181C recombinant reverse transcriptase of HIV-1 IIIB B 4.22 pIC50 >60000 nM IC50 J Med Chem (1996) 39: 3769-3789 [PMID:8809165]
ChEMBL Inhibition of HIV1 RT Y181I mutant B 4.44 pIC50 36000 nM IC50 J Med Chem (2005) 48: 7153-7165 [PMID:16279773]
ChEMBL Inhibition of wild type HIV-1 reverse transcriptase using biotin-labelled dNTPs as substrate incubated for 2 hrs by ELISA B 4.51 pIC50 31000 nM IC50 J Med Chem (2022) 65: 2458-2470 [PMID:35061384]
ChEMBL Inhibition of HIV1 reverse transcriptase Y181I mutant by RNA-dependent DNA polymerase activity assay B 4.52 pIC50 30000 nM IC50 Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079]
ChEMBL Inhibition of HIV1 reverse transcriptase using Poly rA.dT template B 4.64 pIC50 23000 nM IC50 Eur J Med Chem (2007) 42: 993-1003 [PMID:17321639]
ChEMBL Inhibitory activity against recombinant HIV-1 reverse transcriptase (rRT) B 4.64 pIC50 23000 nM IC50 Bioorg Med Chem Lett (1999) 9: 2721-2726 [PMID:10509923]
ChEMBL Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system B 4.64 pIC50 23000 nM IC50 Bioorg Med Chem Lett (1999) 9: 3411-3416 [PMID:10617082]
ChEMBL Compound was evaluated for its inhibitory activity against recombinant HIV-1 Reverse transcriptase using cell free RT inhibition assay B 4.64 pIC50 23000 nM IC50 Bioorg Med Chem Lett (2000) 10: 2071-2074 [PMID:10999473]
ChEMBL Inhibition of purified recombinant HIV-1 reverse transcriptase B 4.64 pIC50 23000 nM IC50 Bioorg Med Chem Lett (1999) 9: 1593-1598 [PMID:10386942]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase Y181I mutant assessed as reduction in enzyme activity B 4.7 pIC50 >20000 nM IC50 J Med Chem (2014) 57: 9945-9957 [PMID:25418038]
ChEMBL Inhibition of HIV1 wild-type reverse transcriptase Y181I/Y181C mutant using [3H]dTTP by scintillation counting B 4.7 pIC50 >20000 nM IC50 Eur J Med Chem (2014) 80: 101-111 [PMID:24769348]
ChEMBL Inhibition of HIV1 reverse transcriptase p66 Y181I mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting analysis B 4.7 pIC50 >20000 nM IC50 J Med Chem (2017) 60: 6528-6547 [PMID:28628334]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase Y181I/Y181C mutant assessed as reduction in enzyme activity B 4.7 pIC50 >20000 nM IC50 J Med Chem (2014) 57: 9945-9957 [PMID:25418038]
ChEMBL Inhibitory activity against HIV rRT activity in mutant HIV-1 strain resistant to Nevirapine (Y181C) B 4.7 pIC50 >20000 nM IC50 J Med Chem (1996) 39: 522-530 [PMID:8558522]
ChEMBL Inhibition of HIV1 RT Y188L mutant B 4.74 pIC50 18000 nM IC50 J Med Chem (2005) 48: 7153-7165 [PMID:16279773]
ChEMBL Inhibition of HIV1 reverse transcriptase p66/p51 L100I mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry B 4.85 pIC50 14000 nM IC50 Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451]
ChEMBL Inhibition of HIV-1 reverse transcriptase L100I mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis B 4.85 pIC50 14000 nM IC50 Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060]
ChEMBL Inhibition of HIV1 reverse transcriptase after 1 hr by ELISA B 4.88 pIC50 13200 nM IC50 Eur J Med Chem (2010) 45: 4096-4103 [PMID:20598780]
ChEMBL Inhibitory effect on recombinant HIV- 1 reverse transcriptase which has a mutation Leu 100 to Ile 100 (clone 118) B 4.89 pIC50 13000 nM IC50 Bioorg Med Chem Lett (1998) 8: 1511-1516 [PMID:9873380]
ChEMBL Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis B 4.92 pIC50 12000 nM IC50 Antimicrob Agents Chemother (2007) 51: 638-644 [PMID:17116672]
ChEMBL Tested for the inhibition of mutant type (Ile100) HIV-1 (IIIB) RT B 4.93 pIC50 11800 nM IC50 J Med Chem (1996) 39: 4261-4274 [PMID:8863804]
ChEMBL Inhibition of RNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase by filter-based filtration assay B 4.96 pIC50 11000 nM IC50 Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127]
ChEMBL Inhibition of HIV1 reverse transcriptase by ELISA B 4.97 pIC50 10600 nM IC50 Bioorg Med Chem (2007) 15: 7399-7407 [PMID:17870545]
ChEMBL Inhibition of HIV1 RT V106A mutant B 5 pIC50 10000 nM IC50 J Med Chem (2005) 48: 7153-7165 [PMID:16279773]
ChEMBL Inhibition of HIV1 isolate R8 reverse transcriptase K103N mutant after 90 mins by electrochemiluminescence analysis B 5.03 pIC50 9300 nM IC50 Antimicrob Agents Chemother (2009) 53: 2424-2431 [PMID:19289522]
ChEMBL Inhibition of HIV1 reverse transcriptase L100I mutant B 5.05 pIC50 9000 nM IC50 Bioorg Med Chem Lett (2011) 21: 3935-3938 [PMID:21636271]
ChEMBL Inhibition of HIV1 reverse transcriptase L100I mutant RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate B 5.05 pIC50 9000 nM IC50 J Med Chem (2012) 55: 6634-6638 [PMID:22712652]
ChEMBL Inhibition of HIV1 RT L100I mutant B 5.05 pIC50 9000 nM IC50 J Med Chem (2005) 48: 7153-7165 [PMID:16279773]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase L100I mutant assessed as reduction in enzyme activity B 5.05 pIC50 9000 nM IC50 J Med Chem (2014) 57: 9945-9957 [PMID:25418038]
ChEMBL Inhibition of HIV1 wild-type reverse transcriptase L100I mutant using [3H]dTTP by scintillation counting B 5.05 pIC50 9000 nM IC50 Eur J Med Chem (2014) 80: 101-111 [PMID:24769348]
ChEMBL Inhibition of HIV1 isolate R8 reverse transcriptase Y181C mutant after 90 mins by electrochemiluminescence analysis B 5.05 pIC50 8900 nM IC50 Antimicrob Agents Chemother (2009) 53: 2424-2431 [PMID:19289522]
ChEMBL Inhibition of wild type HIV1 Reverse transcriptase assessed as reduction of biotin deoxyuridine triphosphate incorporation into the wild type HIV1 reverse transcriptase after 1 hr by ELISA B 5.06 pIC50 8800 nM IC50 Eur J Med Chem (2016) 115: 53-62 [PMID:26994843]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)-oligo(dT) as template/primer and digoxigenin-dUTP/biotin-dUTP/dTTP nucleotides incubated for 1 hr by ELISA B 5.06 pIC50 8800 nM IC50 Eur J Med Chem (2016) 109: 294-304 [PMID:26802545]
ChEMBL Inhibition of HIV-1 reverse transcriptase assessed as reduction in biotin-duTP incorporation using biotin-labeled dUTP and hybrid poly(A)-oligo (dT)15 template primer after 2 hrs by ELISA B 5.06 pIC50 8780 nM IC50 Bioorg Med Chem (2016) 24: 4424-4433 [PMID:27501911]
ChEMBL Inhibition of HIV-1 reverse transcriptase assessed as decrease in incorporation of [3H]TTP into polyA template B 5.12 pIC50 7500 nM IC50 J Nat Prod (2013) 76: 530-537 [PMID:23550966]
ChEMBL Inhibition of HIV1 wild type reverse transcriptase expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting B 5.14 pIC50 7200 nM IC50 Medchemcomm (2013) 4: 741-748
ChEMBL Inhibition of wild-type HIV1 Reverse transcriptase p51/p66 after 30 mins using alpha-[32P]dATP by liquid scintillation counting B 5.14 pIC50 7200 nM IC50 Medchemcomm (2013) 4: 1443-1451
ChEMBL Inhibition of HIV1 reverse transcriptase L100I mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis B 5.15 pIC50 7130 nM IC50 Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311]
ChEMBL Inhibition of HIV1 reverse transcriptase K103N mutant B 5.15 pIC50 7000 nM IC50 Bioorg Med Chem Lett (2011) 21: 3935-3938 [PMID:21636271]
ChEMBL Inhibition of HIV1 reverse transcriptase K103N mutant RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate B 5.15 pIC50 7000 nM IC50 J Med Chem (2012) 55: 6634-6638 [PMID:22712652]
ChEMBL Inhibition of HIV1 wild-type reverse transcriptase K103N mutant using [3H]dTTP by scintillation counting B 5.15 pIC50 7000 nM IC50 Eur J Med Chem (2014) 80: 101-111 [PMID:24769348]
ChEMBL Inhibition of RNA-dependent DNA polymerase activity of recombinant HIV-1 p66/p51 reverse transcriptase K103N mutant assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation counting method B 5.15 pIC50 7000 nM IC50 Eur J Med Chem (2020) 208: 112696-112696 [PMID:32883642]
ChEMBL Inhibition of HIV1 RT K103N mutant B 5.15 pIC50 7000 nM IC50 J Med Chem (2005) 48: 7153-7165 [PMID:16279773]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase K103N mutant assessed as reduction in enzyme activity B 5.15 pIC50 7000 nM IC50 J Med Chem (2014) 57: 9945-9957 [PMID:25418038]
ChEMBL Inhibition of HIV1 reverse transcriptase p66 K103N mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting analysis B 5.15 pIC50 7000 nM IC50 J Med Chem (2017) 60: 6528-6547 [PMID:28628334]
ChEMBL Inhibition of HIV1 reverse transcriptase L100I mutant by RNA-dependent DNA polymerase activity assay B 5.15 pIC50 7000 nM IC50 Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079]
ChEMBL Inhibition of HIV1 reverse transcriptase Y181C mutant in 293T cells B 5.18 pIC50 6650 nM IC50 Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484]
ChEMBL Inhibitory activity against HIV-1 reverse transcriptase B 5.19 pIC50 6440 nM IC50 J Med Chem (1996) 39: 1645-1650 [PMID:8648604]
ChEMBL Ability to inhibit HIV-1 IIIB reverse transcriptase catalyzed incorporation of tritiated thymidine triphosphate onto a biotinylated rA.dT template primer B 5.19 pIC50 6440 nM IC50 Bioorg Med Chem Lett (1992) 2: 1745-1750
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotinylated dUTP incorporation after 1 hr by ELISA B 5.21 pIC50 6200 nM IC50 Bioorg Med Chem (2013) 21: 7091-7100 [PMID:24119448]
ChEMBL Activity of selected HIV-1 N-acylthiocarbamates in enzyme assay against Virion-Associated reverse transcriptase B 5.22 pIC50 6000 nM IC50 J Med Chem (2003) 46: 768-781 [PMID:12593657]
ChEMBL Inhibition of HIV1 reverse transcriptase K103N mutant in 293T cells B 5.24 pIC50 5750 nM IC50 Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484]
ChEMBL In vitro inhibition of HIV-1 reverse transcriptase B 5.26 pIC50 5500 nM IC50 J Med Chem (1993) 36: 1505-1508 [PMID:7684450]
ChEMBL Inhibition of HIV1 RT K103N mutant mediated DNA-dependent DNA polymerization using RNA PPT primed substrate by scintillation proximity assay B 5.3 pIC50 >5000 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL Inhibition of HIV1 RT K103N mutant mediated DNA-dependent DNA polymerization using DNA PPT primed substrate by scintillation proximity assay B 5.3 pIC50 >5000 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL Inhibition of HIV1 RT Y181C mutant mediated DNA-dependent DNA polymerization using RNA/DNAM duplex primed substrate by scintillation proximity assay B 5.3 pIC50 >5000 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL Inhibition of HIV1 RT Y181C mutant mediated DNA-dependent DNA polymerization using RNA PPT primed substrate by scintillation proximity assay B 5.3 pIC50 >5000 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL Inhibition of HIV1 RT Y181C mutant mediated DNA-dependent DNA polymerization using DNA PPT primed substrate by scintillation proximity assay B 5.3 pIC50 >5000 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL Inhibition of HIV1 RT K103N mutant mediated DNA-dependent DNA polymerization using RNA/DNAM duplex primed substrate by scintillation proximity assay B 5.3 pIC50 >5000 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL The compound was evaluated for the inhibition of HIV-1 reverse transcriptase B 5.31 pIC50 4848 nM IC50 Bioorg Med Chem Lett (2000) 10: 193-195 [PMID:10673109]
ChEMBL Inhibition of HIV-1 reverse transcriptase. B 5.31 pIC50 4848 nM IC50 J Med Chem (2000) 43: 2019-2030 [PMID:10821714]
ChEMBL Inhibition of HIV-1 recombinant reverse transcriptase after 1 hr by streptavidinalkaline phosphatase reporter system B 5.33 pIC50 4650 nM IC50 Bioorg Med Chem (2015) 23: 149-159 [PMID:25468035]
ChEMBL Inhibition of HIV1 reverse transcriptase after 1 hr by colorimetric assay B 5.35 pIC50 4450 nM IC50 J Med Chem (2013) 56: 3593-3608 [PMID:23540737]
ChEMBL Inhibition of HIV1 wild type RT using poly(rA)/oligo(dT)15 homopolymer template after 1 hrs by ELISA B 5.36 pIC50 4400 nM IC50 Bioorg Med Chem (2011) 19: 4366-4376 [PMID:21683601]
ChEMBL Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into enzyme by colorimetry B 5.36 pIC50 4390 nM IC50 Eur J Med Chem (2011) 46: 5039-5045 [PMID:21872971]
ChEMBL Inhibition of HIV1 reverse transcriptase using poly(ra)/oligo(dT)15 homopolymer template as substrate after 1 hr B 5.39 pIC50 4120 nM IC50 J Med Chem (2012) 55: 2242-2250 [PMID:22283377]
ChEMBL Inhibition of biotin-dUTP labeled HIV-1 reverse transcriptase after 30 mins colorimetric streptavidin alkaline phosphatase reporter system B 5.39 pIC50 4120 nM IC50 Bioorg Med Chem Lett (2010) 20: 3003-3005 [PMID:20347295]
ChEMBL Inhibition of HIV1 reverse transcriptase by ELISA B 5.39 pIC50 4120 nM IC50 Bioorg Med Chem (2010) 18: 3231-3237 [PMID:20371182]
ChEMBL Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by filter-based filtration assay B 5.39 pIC50 4100 nM IC50 Antimicrob Agents Chemother (2010) 54: 2401-2408 [PMID:20308384]
ChEMBL Inhibition of HIV1 reverse transcriptase K103N mutant by RNA-dependent DNA polymerase activity assay B 5.4 pIC50 4000 nM IC50 Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079]
ChEMBL Inhibitory activity against HIV-1 Mutant Reverse transcriptase V106A B 5.41 pIC50 3930 nM IC50 J Med Chem (1998) 41: 2972-2984 [PMID:9685236]
ChEMBL Inhibitory activity against HIV rRT activity in HIV-1 mutant resistant to TIBO(L100I) strain B 5.46 pIC50 3500 nM IC50 J Med Chem (1996) 39: 522-530 [PMID:8558522]
ChEMBL Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (Y181C) B 5.49 pIC50 3200 nM IC50 Bioorg Med Chem Lett (1998) 8: 2169-2172 [PMID:9873507]
ChEMBL Inhibition of DNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by gel-based primer extension assay B 5.49 pIC50 3200 nM IC50 Antimicrob Agents Chemother (2010) 54: 2401-2408 [PMID:20308384]
ChEMBL In vitro ability to inhibit wild type resistant (WT) reverse transcriptase B 5.51 pIC50 3100 nM IC50 J Med Chem (2000) 43: 1034-1040 [PMID:10715167]
ChEMBL In vitro inhibition of recombinant reverse transcriptase (WT) of HIV-1 IIIB B 5.51 pIC50 3100 nM IC50 J Med Chem (1996) 39: 3769-3789 [PMID:8809165]
ChEMBL Inhibitory concentration against HIV-Reverse transcriptase B 5.52 pIC50 3000 nM IC50 Bioorg Med Chem Lett (2005) 15: 1107-1109 [PMID:15686922]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as incorporation of biotin-dUTP into poly(rA)-oligo(dT) B 5.56 pIC50 2740 nM IC50 Eur J Med Chem (2012) 51: 60-66 [PMID:22405288]
ChEMBL Inhibition of recombinant wild type HIV1 RT using poly(rA)/oligo(dT)16 as template after 40 mins by spectrofluorometric analysis B 5.56 pIC50 2740 nM IC50 Eur J Med Chem (2013) 65: 134-143 [PMID:23707918]
ChEMBL Inhibition of purified recombinant HIV-1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation using poly(rC)-oligo(dG) as template primer B 5.56 pIC50 2740 nM IC50 Medchemcomm (2013) 4: 810-816
ChEMBL Inhibition of HIV1 recombinant reverse transcriptase assessed as incorporation of biotin-dUTP into poly(rC)-oligo(dG) by colorimetric analysis B 5.57 pIC50 2700 nM IC50 Bioorg Med Chem (2012) 20: 6795-6802 [PMID:23098609]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as biotin-dUTP incorporation into enzyme using poly(rC)-oligo(dG) as template primer by colorimetric analysis B 5.57 pIC50 2700 nM IC50 Bioorg Med Chem Lett (2012) 22: 7155-7162 [PMID:23084898]
ChEMBL Inhibitory activity against HIV-1 Y181C Reverse transcriptase (RT) B 5.59 pIC50 2600 nM IC50 J Med Chem (1995) 38: 4830-4838 [PMID:7490732]
ChEMBL Compound was evaluated for inhibition of Y181C HIV type I reverse transcriptase. B 5.59 pIC50 2600 nM IC50 J Med Chem (1995) 38: 4839-4847 [PMID:7490733]
ChEMBL Inhibition of GST-tagged recombinant wild type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 using dTTP as substrate after 40 mins by spectrofluorometric analysis B 5.59 pIC50 2550 nM IC50 Bioorg Med Chem (2014) 22: 1459-1467 [PMID:24457088]
ChEMBL Inhibition of HIV1 reverse transcriptase using Poly rC.dG template B 5.6 pIC50 2500 nM IC50 Eur J Med Chem (2007) 42: 993-1003 [PMID:17321639]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotinylated dUTP incorporation after 1 hr by ELISA B 5.6 pIC50 2500 nM IC50 Bioorg Med Chem (2014) 22: 1863-1872 [PMID:24581546]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-labeled dUTP incorporation into DNA using poly(A) x oligo(dT)15 as template/primer after 1 hr by ELISA B 5.62 pIC50 2400 nM IC50 Eur J Med Chem (2015) 93: 330-337 [PMID:25707013]
ChEMBL Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 assessed as reduction in biotin-dUTP incorporation incubated for 40 mins using poly(rA) template and oligo(dT)16 primer by picogreen dye based spectrofluorometry B 5.63 pIC50 2320 nM IC50 Eur J Med Chem (2017) 140: 383-391 [PMID:28987601]
ChEMBL Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as decrease in biotin-dUTP incorporation using DIG-labeled dUTP/biotin-labeled dUTP and dTTP as template and viral nucleotides after 1 hr by ELISA B 5.63 pIC50 2320 nM IC50 ACS Med Chem Lett (2018) 9: 334-338 [PMID:29670696]
ChEMBL Ability to inhibit HIV-1 IIIB reverse transcriptase catalyzed incorporation of tritiated thymidine triphosphate onto a biotinylated rN.dN template primer B 5.68 pIC50 2110 nM IC50 Bioorg Med Chem Lett (1992) 2: 1745-1750
ChEMBL Inhibition of HIV1 reverse transcriptase V179D mutant B 5.7 pIC50 2000 nM IC50 Bioorg Med Chem Lett (2011) 21: 3935-3938 [PMID:21636271]
ChEMBL Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis B 5.7 pIC50 2000 nM IC50 Antimicrob Agents Chemother (2007) 51: 638-644 [PMID:17116672]
ChEMBL Inhibitory activity against HIV-1 Mutant Reverse transcriptase K103N B 5.72 pIC50 1900 nM IC50 J Med Chem (1998) 41: 2960-2971 [PMID:9685235]
ChEMBL Inhibitory concentration against mutant reverse transcriptase of K103N was determined which is in turn resistant to pyridinones B 5.72 pIC50 1900 nM IC50 J Med Chem (1995) 38: 4830-4838 [PMID:7490732]
ChEMBL Inhibitory activity against HIV-1 Mutant Reverse transcriptase K103N B 5.73 pIC50 1850 nM IC50 J Med Chem (1998) 41: 2972-2984 [PMID:9685236]
ChEMBL Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin-labeled dUTP incorporation into DNA using polyr(A) x oligo(dT)16 template/primer hybrid B 5.75 pIC50 1795 nM IC50 Eur J Med Chem (2015) 97: 1-9 [PMID:25935383]
ChEMBL Inhibition of wild-type HIV1 reverse transcriptase p66/p51 after 40 mins by spectrophotometry B 5.75 pIC50 1780 nM IC50 Bioorg Med Chem (2014) 22: 2535-2541 [PMID:24680058]
ChEMBL Inhibition of HIV-1 wild type recombinant reverse transcriptase p66/p51 assessed as RNA-DNA heteroduplex formation using poly(rA) template/oligo(dT)16 primer incubated prior to enzyme addition by spectrofluorometer analysis B 5.75 pIC50 1780 nM IC50 Medchemcomm (2014) 5: 468-473
ChEMBL Inhibition of recombinant wild type HIV-1 reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 (1:1.2) as template/primer after 40 mins by spectrofluorometric analysis B 5.75 pIC50 1780 nM IC50 Bioorg Med Chem (2013) 21: 6477-6483 [PMID:24055077]
ChEMBL Inhibition of HIV1 wild type p66/p51 reverse transcriptase B 5.77 pIC50 1700 nM IC50 J Med Chem (2007) 50: 2370-2384 [PMID:17458947]
ChEMBL Inhibition of RNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity B 5.77 pIC50 1700 nM IC50 J Med Chem (2008) 51: 5702-5713 [PMID:18800765]
ChEMBL Inhibition of DNA polymerase activity of HIV1 reverse transcriptase B 5.77 pIC50 1700 nM IC50 J Med Chem (2007) 50: 2370-2384 [PMID:17458947]
ChEMBL Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin dUTP incorporation by primer extension assay B 5.77 pIC50 1700 nM IC50 Bioorg Med Chem (2013) 21: 7398-7405 [PMID:24134904]
ChEMBL Inhibition of HIV1 reverse transcriptase p66/p51 assessed as inhibition of biotin-dUTP incorporation using poly (rA)/oligo(dT)16 as template/primer incubated for 40 mins B 5.78 pIC50 1650 nM IC50 Eur J Med Chem (2015) 102: 215-222 [PMID:26276435]
ChEMBL Inhibition of wild type recombinant HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by picogreen dye-based spectrofluorometric method B 5.81 pIC50 1550 nM IC50 Bioorg Med Chem (2020) 28: 115431-115431 [PMID:32197813]
ChEMBL Inhibition of recombinant wild-type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis B 5.81 pIC50 1550 nM IC50 Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060]
ChEMBL Inhibition of recombinant wild-type HIV-1 3B reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis B 5.81 pIC50 1550 nM IC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Inhibition of recombinant HIV1 Reverse transcriptase p66/p51 using poly (rA)-oligo (dT) as template primer after 40 mins by spectrofluorometric analysis B 5.82 pIC50 1528 nM IC50 Bioorg Med Chem (2015) 23: 6587-6593 [PMID:26385446]
ChEMBL Inhibitory activity against HIV-1 Mutant Reverse transcriptase P236L B 5.83 pIC50 1480 nM IC50 J Med Chem (1998) 41: 2972-2984 [PMID:9685236]
ChEMBL Inhibition of recombinant wild type HIV1 reverse transcriptase using DIG-labeled dUTP/biotin-labeled dUTP and dTTP as template and viral nucleotides assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA B 5.86 pIC50 1390 nM IC50 ACS Med Chem Lett (2017) 8: 1188-1193 [PMID:29152052]
ChEMBL Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 using dsDNA by microplate reader based assay B 5.87 pIC50 1350 nM IC50 Bioorg Med Chem (2014) 22: 4658-4666 [PMID:25127466]
ChEMBL Inhibition of recombinant wild type HIV1 p66/p51 using poly(rA) template/oligo(dT)16 primer after 40 mins by PicoGreen-based spectrofluorometric method B 5.87 pIC50 1350 nM IC50 Eur J Med Chem (2016) 121: 352-363 [PMID:27267005]
ChEMBL Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (K103N) B 5.89 pIC50 1300 nM IC50 Bioorg Med Chem Lett (1998) 8: 2169-2172 [PMID:9873507]
ChEMBL Inhibition of HIV 1 reverse transcriptase assessed as incorporation of biotin-dUTP into poly rA.dT by ELISA B 5.92 pIC50 1200 nM IC50 Bioorg Med Chem (2013) 21: 2128-2134 [PMID:23415090]
ChEMBL Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 pre-incubated with compound before enzyme addition using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry B 5.94 pIC50 1150 nM IC50 Bioorg Med Chem (2015) 23: 1069-1081 [PMID:25638501]
ChEMBL Inhibition of HIV-1 reverse transcriptase E138K mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis B 5.95 pIC50 1130 nM IC50 Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060]
ChEMBL Covalent inhibition of recombinant wild type HIV-1 reverse transcriptase using poly(rA)350/oligo(dT)16 as template/primer preincubated followed by substrate addition measured after 1 hr by pico-green reagent based fluorescence analysis B 5.97 pIC50 1060 nM IC50 ACS Med Chem Lett (2021) 12: 249-255 [PMID:33603971]
ChEMBL Inhibition of wild type HIV1 p66/p51 reverse transcriptase by spectrofluorometry B 6 pIC50 1000 nM IC50 Bioorg Med Chem (2015) 23: 624-631 [PMID:25537532]
ChEMBL Inhibition of HIV1 reverse transcriptase using 234-nt long RNA/18-mer DNA oligonucleotide as template/primer preincubated for 15 mins followed by incubation with template/primer for 40 mins by liquid scintillation counting in presence of alpha[P33]-dCTP B 6.04 pIC50 920 nM IC50 Bioorg Med Chem (2016) 24: 2519-2529 [PMID:27108399]
ChEMBL Inhibition of HIV1 wild type reverse transcriptase p66/p51 using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry B 6.04 pIC50 910 nM IC50 Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase using poly (A)/oligo (dT)15 as template/primer assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA B 6.05 pIC50 900 nM IC50 Bioorg Med Chem (2018) 26: 2051-2060 [PMID:29559197]
ChEMBL Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA PPT primed substrate by scintillation proximity assay B 6.05 pIC50 900 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation using hybrid poly (A).oligo (dT)15 template primer incubated for 1 hr at 37 degC by ELISA method B 6.05 pIC50 900 nM IC50 Bioorg Med Chem (2014) 22: 5290-5297 [PMID:25150090]
ChEMBL Inhibition of wild type HIV-1 reverse transcriptase assessed as assessed as inhibition of biotin deoxyuridine triphosphate incorporation into protein B 6.05 pIC50 890 nM IC50 Eur J Med Chem (2023) 247: 115042-115042 [PMID:36577220]
ChEMBL Inhibition of HIV1 reverse transcriptase Y188C mutant in 293T cells B 6.07 pIC50 860 nM IC50 Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484]
ChEMBL Inhibition of HIV1 reverse transcriptase E138K mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis B 6.07 pIC50 860 nM IC50 Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311]
ChEMBL Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin deoxyuridine triphosphate (biotin-dUTP) incorporation using poly(rA)/oligo (dT)16 template and primer by spectrofluorometry B 6.09 pIC50 807 nM IC50 Bioorg Med Chem (2015) 23: 4248-4255 [PMID:26162497]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into protein incubated for 1 hrs by ELISA B 6.11 pIC50 778 nM IC50 J Med Chem (2021) 64: 13658-13675 [PMID:34432448]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into protein incubated for 1 hrs by ELISA B 6.11 pIC50 778 nM IC50 J Med Chem (2021) 64: 13658-13675 [PMID:34432448]
ChEMBL Inhibition of recombinant wild-type p66/p51 HIV-1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis B 6.15 pIC50 705 nM IC50 Eur J Med Chem (2022) 238: 114512-114512 [PMID:35679690]
ChEMBL Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase DNA-dependent DNA polymerase activity by gel-based primer extension assay B 6.15 pIC50 700 nM IC50 Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as residual enzyme activity at 50 uM after 1 hr by ELISA B 6.17 pIC50 670 nM IC50 Bioorg Med Chem (2011) 19: 4227-4237 [PMID:21700466]
ChEMBL Inhibition of wild-type HIV1 reverse transcriptase assessed as incorporation of biotin-labeled dUTP B 6.17 pIC50 670 nM IC50 Bioorg Med Chem (2014) 22: 633-642 [PMID:24275349]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into template incubated for 1 hr by ELISA B 6.19 pIC50 645.65 nM IC50 Eur J Med Chem (2021) 213: 113051-113051 [PMID:33279288]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into template incubated for 1 hr by ELISA B 6.19 pIC50 640 nM IC50 Eur J Med Chem (2021) 213: 113051-113051 [PMID:33279288]
ChEMBL Inhibition of wild type HIV-1 reverse transcriptase assessed as reduction of biotin-dUTP incorporation into protein using ABTS as substrate incubated for 1 hrs by ELISA analysis B 6.2 pIC50 638 nM IC50 Eur J Med Chem (2023) 246: 114957-114957 [PMID:36446205]
ChEMBL Inhibition of DNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity B 6.2 pIC50 630 nM IC50 J Med Chem (2008) 51: 5702-5713 [PMID:18800765]
ChEMBL HIV-1 reverse transcriptase inhibitory activity against Asn103 mutant using (poly)rC600*(oligo)dGT as template primer. B 6.2 pIC50 625 nM IC50 J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)-oligo(dT) as template/primer and digoxigenin-/biotin-labeled dUTP nucleotides incubated for 1 hr B 6.21 pIC50 620 nM IC50 Eur J Med Chem (2014) 87: 52-62 [PMID:25240095]
ChEMBL Inhibition of wild-type HIV1 Reverse transcriptase p66/p51 assessed as relative fluorescence signal after 40 mins B 6.21 pIC50 620 nM IC50 Bioorg Med Chem (2015) 23: 3860-3868 [PMID:25907370]
ChEMBL Inhibitory activity against HIV rRT activity in wild type IIIB strain B 6.22 pIC50 600 nM IC50 J Med Chem (1996) 39: 522-530 [PMID:8558522]
ChEMBL Inhibition of HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by pico-green based spectrofluorometric analysis B 6.23 pIC50 595 nM IC50 J Med Chem (2019) 62: 2083-2098 [PMID:30721060]
ChEMBL Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(A)/oligo(dT)15 as template/primer after 1 hr by ELISA B 6.23 pIC50 595 nM IC50 Bioorg Med Chem (2019) 27: 447-456 [PMID:30606670]
ChEMBL Inhibition of wild-type HIV1 reverse transcriptase infected in human MT4 cells assessed as reduction in biotin-dUTP incorporation B 6.23 pIC50 590 nM IC50 ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into template incubated for 1 hr by ELISA B 6.23 pIC50 590 nM IC50 Eur J Med Chem (2019) 182: 111619-111619 [PMID:31434039]
ChEMBL Inhibition of HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by pico-green based spectrofluorometric analysis B 6.23 pIC50 588.84 nM IC50 J Med Chem (2019) 62: 2083-2098 [PMID:30721060]
ChEMBL Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-labeled dUTP incorporation into DNA after 1 hr using poly(A) x oligo(dT)15 template/primer hybrid, digoxigenin and biotin-labeled nucleotides B 6.24 pIC50 580 nM IC50 Eur J Med Chem (2015) 92: 754-765 [PMID:25626145]
ChEMBL Inhibition of recombinant wild-type HIV1 p66/p51 reverse transcriptase assessed as inhibition of [3H]dGTP incorporation using poly (rA) as templates incubated for 40 mins by spectrofluorometer B 6.24 pIC50 580 nM IC50 J Med Chem (2021) 64: 10297-10311 [PMID:34197708]
ChEMBL Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis B 6.24 pIC50 580 nM IC50 J Med Chem (2021) 64: 5067-5081 [PMID:33851529]
ChEMBL Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis B 6.24 pIC50 580 nM IC50 J Med Chem (2022) 65: 2122-2138 [PMID:35073089]
ChEMBL Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into wild type RT measured after 1 hr by ELISA B 6.24 pIC50 575 nM IC50 Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378]
ChEMBL Inhibition of recombinant HIV-1 BH10 reverse transcriptase p51/p66 expressed in Escherichia coli preincubated for 10 mins followed by D38/25PGA template-primer addition and measured after 10 to 30 secs by denaturing PAGE based single nucleotide incorporation assay B 6.24 pIC50 570 nM IC50 ACS Med Chem Lett (2020) 11: 811-817 [PMID:32435389]
ChEMBL Inhibition of HIV-1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorometric analysis B 6.26 pIC50 552 nM IC50 J Med Chem (2022) 65: 8478-8492 [PMID:35649164]
ChEMBL Inhibition of recombinant HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation in to poly [A] x oligo[dT]15 by ELISA B 6.26 pIC50 550 nM IC50 Bioorg Med Chem (2014) 22: 2052-2059 [PMID:24631361]
ChEMBL Inhibition of recombinant HIV1 reverse transcriptase using poly rA:dT as template/primer after 1 hr by ELISA B 6.29 pIC50 510 nM IC50 Bioorg Med Chem Lett (2013) 23: 6593-6597 [PMID:24239481]
ChEMBL Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into template B 6.29 pIC50 510 nM IC50 J Med Chem (2021) 64: 4239-4256 [PMID:33734714]
ChEMBL Compound was tested for Inhibition of HIV-1 RT activity. B 6.3 pIC50 500 nM IC50 J Med Chem (1996) 39: 2672-2680 [PMID:8709096]
ChEMBL Inhibition of RNA-dependent DNA polymerase activity of Human immunodeficiency virus 1 recombinant reverse transcriptase expressed in Escherichia coli using poly(rA)oligo(dT) template primer after 30 min B 6.3 pIC50 500 nM IC50 Med Chem Res (2006) 15: 492-510
ChEMBL Inhibition of recombinant HIV1 reverse transcriptase by colorimetric assay B 6.3 pIC50 <500 nM IC50 Eur J Med Chem (2021) 224: 113681-113681 [PMID:34246921]
ChEMBL Inhibition of HIV-1 reverse transcriptase using [2,8-3H]dGTP as substrate by fluorescence based assay B 6.31 pIC50 490 nM IC50 Eur J Med Chem (2023) 248: 115114-115114 [PMID:36640458]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis B 6.32 pIC50 480 nM IC50 Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311]
ChEMBL Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA/DNAM duplex primed substrate by scintillation proximity assay B 6.35 pIC50 450 nM IC50 J Biol Chem (2007) 282: 8005-8010 [PMID:17172472]
ChEMBL Inhibitory activity against HIV-1 reverse transcriptase (HIV-RT) B 6.37 pIC50 430 nM IC50 J Med Chem (1993) 36: 2526-2535 [PMID:7689109]
ChEMBL In vitro for inhibitory activity against HIV-1 Reverse Transcriptase B 6.37 pIC50 430 nM IC50 J Med Chem (1993) 36: 726-732 [PMID:7681480]
ChEMBL Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye-based spectrofluorometric analysis B 6.39 pIC50 404 nM IC50 J Med Chem (2019) 62: 11430-11436 [PMID:31714780]
ChEMBL Inhibition of recombinant HIV-1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye based spectrofluorometric assay B 6.39 pIC50 404 nM IC50 Eur J Med Chem (2019) 182: 111603-111603 [PMID:31421633]
ChEMBL Inhibition of recombinant wild type HIV-1 reverse transcriptase using DNA/RNA as substrate incubated for 40 mins by Pico-green dye based spectrofluorometric analysis B 6.39 pIC50 404 nM IC50 J Med Chem (2023) 66: 4755-4767 [PMID:36996328]
ChEMBL Inhibition of RNA-dependent DNA polymerase activity of wild type recombinant HIV-1 His-tagged p66/p51 reverse transcriptase assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation counting method B 6.4 pIC50 400 nM IC50 Eur J Med Chem (2020) 208: 112696-112696 [PMID:32883642]
ChEMBL Inhibition of HIV1 wild type reverse transcriptase B 6.4 pIC50 400 nM IC50 Bioorg Med Chem Lett (2011) 21: 3935-3938 [PMID:21636271]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate B 6.4 pIC50 400 nM IC50 J Med Chem (2012) 55: 6634-6638 [PMID:22712652]
ChEMBL Inhibition of HIV1 wild-type reverse transcriptase using [3H]dTTP by scintillation counting B 6.4 pIC50 400 nM IC50 Eur J Med Chem (2014) 80: 101-111 [PMID:24769348]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase assessed as reduction in enzyme activity B 6.4 pIC50 400 nM IC50 J Med Chem (2014) 57: 9945-9957 [PMID:25418038]
ChEMBL Inhibition of HIV1 NL4-3 reverse transcriptase His-tagged p66/p51 associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting analysis B 6.4 pIC50 400 nM IC50 J Med Chem (2017) 60: 6528-6547 [PMID:28628334]
ChEMBL Inhibition of HIV1 Reverse transcriptase incubated for 30 mins by fluorescence based analysis B 6.4 pIC50 400 nM IC50 J Med Chem (2023) 66: 6193-6217 [PMID:37130343]
ChEMBL Inhibition of wild type HIV-1 reverse transcriptase assessed as inhibition of biotin deoxyuridine triphosphate incorporation into protein B 6.42 pIC50 380 nM IC50 Eur J Med Chem (2023) 246: 114939-114939 [PMID:36442370]
ChEMBL Inhibition of recombinant wild-type HIV1 GST-fused reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis B 6.49 pIC50 323 nM IC50 Bioorg Med Chem Lett (2018) 28: 3491-3495 [PMID:30318436]
ChEMBL In vitro inhibition of mutant P236L recombinant reverse transcriptase of HIV-1 IIIB B 6.49 pIC50 320 nM IC50 J Med Chem (1996) 39: 3769-3789 [PMID:8809165]
ChEMBL In vitro ability to inhibit mutant P236L reverse transcriptase B 6.49 pIC50 320 nM IC50 J Med Chem (2000) 43: 1034-1040 [PMID:10715167]
ChEMBL Inhibition of recombinant wild type HIV-1 His-tagged reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 as template/primer incubated for 40 mins by pico-green based spectrofluorometric analysis B 6.49 pIC50 320 nM IC50 Eur J Med Chem (2020) 185: 111874-111874 [PMID:31735575]
ChEMBL Inhibition of HIV-1 reverse transcriptase assessed as assessed as reduction of biotin-dUTP incorporation into protein incubated for 1 hrs by ELISA analysis B 6.5 pIC50 315 nM IC50 J Med Chem (2023) 66: 8643-8665 [PMID:37255025]
ChEMBL Inhibitory activity against HIV-1 recombinant reverse transcriptase. B 6.52 pIC50 300 nM IC50 J Med Chem (2001) 44: 2544-2554 [PMID:11472208]
ChEMBL Concentration required for 50% inhibition of wild type human immunodeficiency virus type 1 reverse transcriptase B 6.52 pIC50 300 nM IC50 J Med Chem (2004) 47: 5912-5922 [PMID:15537346]
ChEMBL Concentration required to inhibit the HIV-1 reverse transcriptase activity by 50%. B 6.52 pIC50 300 nM IC50 J Med Chem (1999) 42: 619-627 [PMID:10052969]
ChEMBL Inhibition of reverse transcriptase activity of HIV-1 in the presence of [alpha35 S] TTP as cosubstrate B 6.55 pIC50 280 nM IC50 J Med Chem (1993) 36: 3784-3794 [PMID:7504733]
ChEMBL Compound concentration required to inhibit the HIV-1 recombinant Reverse transcriptase (rRT) activity by 50%. B 6.57 pIC50 270 nM IC50 J Med Chem (1997) 40: 1447-1454 [PMID:9154967]
ChEMBL Inhibition of HIV1 reverse transcriptase B 6.6 pIC50 250 nM IC50 Eur J Med Chem (2011) 46: 106-121 [PMID:21093117]
ChEMBL Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells F 6.6 pIC50 250 nM IC50 Bioorg Med Chem Lett (2004) 14: 3173-3176 [PMID:15149669]
ChEMBL Inhibition of HIV-1 recombinant reverse transcriptase B 6.6 pIC50 250 nM IC50 Bioorg Med Chem Lett (1997) 7: 1931-1936
ChEMBL Inhibitory concentration against wild-type reverse transcriptase of HIV-1 B 6.64 pIC50 230 nM IC50 J Med Chem (2004) 47: 1175-1182 [PMID:14971897]
ChEMBL Tested for inhibitory concentration on HIV-1 Reverse transcriptase in the presence of poly(c)-oligo-(dG) B 6.7 pIC50 200 nM IC50 J Med Chem (2000) 43: 3949-3962 [PMID:11052800]
ChEMBL Inhibition of HIV-1 reverse transcriptase using rCdG as template and dGTP as substrate B 6.7 pIC50 200 nM IC50 J Med Chem (1995) 38: 4929-4936 [PMID:8523406]
ChEMBL Inhibitory effect on wild type HIV- 1 reverse transcriptase using rCdG as template and dGTP as substrate. B 6.7 pIC50 200 nM IC50 Bioorg Med Chem Lett (1998) 8: 1511-1516 [PMID:9873380]
ChEMBL Tested for the inhibition of wild type HIV-1 (IIIB) RT B 6.7 pIC50 200 nM IC50 J Med Chem (1996) 39: 4261-4274 [PMID:8863804]
ChEMBL Inhibition of recombinant HIV-1 reverse transcriptase incubated for 2 hrs by colorimetric assay B 6.7 pIC50 200 nM IC50 J Med Chem (2021) 64: 16530-16540 [PMID:34735153]
ChEMBL Inhibition of recombinant HIV-1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation in to cDNA chain incubated for 1 hr by ELISA B 6.74 pIC50 181 nM IC50 J Med Chem (2020) 63: 1298-1312 [PMID:31935327]
ChEMBL Inhibition of HIV1 recombinant RNA-dependent DNA polymerase activity of reverse transcriptase assessed as incorporation of radioactive dTTP into poly(rA)/oligo(dT) B 6.74 pIC50 180 nM IC50 Bioorg Med Chem (2009) 17: 5962-5967 [PMID:19616956]
ChEMBL Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (P236L) B 6.74 pIC50 180 nM IC50 Bioorg Med Chem Lett (1998) 8: 2169-2172 [PMID:9873507]
ChEMBL Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase using poly(rA)/pligo(dT) template B 6.74 pIC50 180 nM IC50 Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079]
ChEMBL Inhibition of HIV1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as incorporation of radioactive dTTP into poly(rA)/oligo(DT) B 6.74 pIC50 180 nM IC50 Bioorg Med Chem (2008) 16: 7429-7435 [PMID:18585918]
ChEMBL Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase B 6.74 pIC50 180 nM IC50 Bioorg Med Chem Lett (2007) 17: 1956-1960 [PMID:17276064]
ChEMBL Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 using poly (rA)/anoligo (dT)16 as template/primer assessed as inhibition of biotin-dUTP incorporation after 40 mins by Pico-Green staining based fluorescence assay B 6.75 pIC50 176 nM IC50 Eur J Med Chem (2018) 145: 726-734 [PMID:29353724]
ChEMBL Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (L1001) B 6.77 pIC50 170 nM IC50 Bioorg Med Chem Lett (1998) 8: 2169-2172 [PMID:9873507]
ChEMBL Inhibition of HIV1 RT using 17-mer DNA/Alexa Fluor 488 5'-end labeled DNA/Alexa Fluor 555-aha-dUTP as primer/template/substrate preincubated for 10 mins followed substarte addition measured after 30 mins by FRET assay B 6.8 pIC50 160 nM IC50 Bioorg Med Chem Lett (2016) 26: 4101-4105 [PMID:27390064]
ChEMBL Inhibition of HIV1 isolate R8 reverse transcriptase after 90 mins B 6.86 pIC50 137 nM IC50 Antimicrob Agents Chemother (2009) 53: 2424-2431 [PMID:19289522]
ChEMBL Inhibitory concentration against mutant reverse transcriptase of L100I was determined which is in turn resistant TIBO B 6.89 pIC50 130 nM IC50 J Med Chem (1995) 38: 4830-4838 [PMID:7490732]
ChEMBL HIV-1 reverse transcriptase inhibitory activity against Ile 100 mutant using (poly)rC600*(oligo)dGT as template primer. B 6.89 pIC50 130 nM IC50 J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL Inhibition of recombinant HIV1 His-tagged p66/p51 reverse transcriptase expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)-oligo(dT) (12 to 18 bp) as template/primer incubated for 20 mins by scintillation counting method B 6.9 pIC50 125 nM IC50 J Med Chem (2016) 59: 2747-2759 [PMID:26898379]
ChEMBL HIV-1 reverse transcriptase inhibitory activity against Cys181 mutant using (poly)rC600*(oligo)dGT as template primer. B 6.94 pIC50 114 nM IC50 J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL Inhibitory concentration against mutant reverse transcriptase of E138K was determined which is in turn resistant to TSAO B 6.96 pIC50 110 nM IC50 J Med Chem (1995) 38: 4830-4838 [PMID:7490732]
ChEMBL Inhibition of wild-type HIV1 reverse transcriptase in HIV1 infected HEK293T cells harboring luciferase gene assessed as reduction in viral infection after 48 hrs by Bright-Glo luciferase assay B 6.98 pIC50 105 nM IC50 ACS Med Chem Lett (2019) 10: 196-202 [PMID:30783503]
ChEMBL Inhibition of HIV1 reverse transcriptase using T19-Cy5 labeled 23-mer DNA/T2-TAMRA labeled 63-mer DNA as primer/template assessed as inhibition of dNTP incorporation into primer/template B 7 pIC50 100 nM IC50 J Med Chem (2016) 59: 7212-7222 [PMID:27339173]
ChEMBL Inhibition of HIV1 reverse transcriptase derived from HIV patient plasma by LC/MS/MS analysis B 7.08 pIC50 84 nM IC50 J Med Chem (2019) 62: 4851-4883 [PMID:30516990]
ChEMBL Inhibition of HIV1 reverse transcriptase B 7.08 pIC50 84 nM IC50 Bioorg Med Chem Lett (2008) 18: 469-473 [PMID:18083556]
ChEMBL In vitro for inhibition of HIV-1 reverse transcriptase. B 7.08 pIC50 84 nM IC50 J Med Chem (1995) 38: 1406-1410 [PMID:7537334]
ChEMBL In vitro inhibitory activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) B 7.08 pIC50 84 nM IC50 J Med Chem (1991) 34: 2231-2241 [PMID:1712395]
ChEMBL Inhibition of HIV-1 reverse transcriptase at 37 degree Centigrade B 7.08 pIC50 84 nM IC50 J Med Chem (2001) 44: 145-154 [PMID:11170624]
ChEMBL Inhibition of HIV1 reverse transcriptase B 7.08 pIC50 84 nM IC50 Bioorg Med Chem Lett (2008) 18: 1530-1533 [PMID:18222088]
ChEMBL Inhibitory activity against HIV-1 Reverse transcriptase (RT) was determined B 7.08 pIC50 84 nM IC50 Bioorg Med Chem Lett (1995) 5: 163-166
ChEMBL Compound was evaluated for inhibition of WT HIV type I reverse transcriptase. B 7.1 pIC50 80 nM IC50 J Med Chem (1995) 38: 4839-4847 [PMID:7490733]
ChEMBL Inhibitory activity against HIV-1 Mutant Reverse transcriptase P236L B 7.1 pIC50 80 nM IC50 J Med Chem (1998) 41: 2960-2971 [PMID:9685235]
ChEMBL Inhibitory activity against HIV-1 Mutant Reverse transcriptase G190A B 7.1 pIC50 80 nM IC50 J Med Chem (1998) 41: 2972-2984 [PMID:9685236]
ChEMBL Inhibitory concentration against HIV-1 wild type Reverse transcriptase (RT) B 7.1 pIC50 80 nM IC50 J Med Chem (1995) 38: 4830-4838 [PMID:7490732]
ChEMBL Inhibitory concentration against mutant reverse transcriptase of P236L was determined which is in turn resistant to BHAP B 7.1 pIC50 80 nM IC50 J Med Chem (1995) 38: 4830-4838 [PMID:7490732]
ChEMBL Ability to inhibit HIV-1 Reverse Transcriptase (RT) using an rC-dG template/primer B 7.14 pIC50 73 nM IC50 J Med Chem (1994) 37: 2437-2444 [PMID:7520079]
ChEMBL In vitro inhibitory concentration against HIV-1 reverse transcriptase using rC-dG template primer B 7.14 pIC50 73 nM IC50 J Med Chem (1993) 36: 249-255 [PMID:7678654]
ChEMBL Inhibition of wild type HIV1 reverse transcriptase in 293T cells B 7.22 pIC50 60 nM IC50 Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484]
ChEMBL Compound was tested for inhibitory activity against HIV-1 wild type reverse transcriptase B 7.22 pIC50 60 nM IC50 Bioorg Med Chem Lett (1998) 8: 2169-2172 [PMID:9873507]
ChEMBL Inhibition of reverse transcriptase activity in HIV1 infected HeLa-MAGI cells at 37 deg C after 48 hrs B 7.3 pIC50 50 nM IC50 Antimicrob Agents Chemother (2007) 51: 638-644 [PMID:17116672]
ChEMBL Inhibition of recombinant wild-type HIV1 3B reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template primer incubated for 1 hr followed by the addition of (DIG)-dUTP and biotin-labeled dNTPs by ELISA B 8.72 pIC50 1.9 nM IC50 Eur J Med Chem (2019) 176: 11-20 [PMID:31091477]
ChEMBL HIV-1 reverse transcriptase inhibitory activity against Wild Type Reverse transcriptase using (poly)rC600*(oligo)dGT as template primer. B 8.89 pIC50 1.3 nM IC50 J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay B 4.82 pEC50 >15020 nM EC50 ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703]
ChEMBL Inhibition of HIV1 3B reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL Inhibition of reverse transcriptase K103N/Y181C double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Inhibition of reverse transcriptase F227L/V106A double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Inhibition of reverse transcriptase Y188L mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Inhibition of reverse transcriptase Y181C mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay B 4.82 pEC50 >15000 nM EC50 Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514]
ChEMBL Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL Inhibition of HIV1 3B reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL Inhibition of HIV1 3B reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 4.82 pEC50 >15000 nM EC50 J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL Inhibition of HIV RT K103N/Y181C mutant by cell based assay B 5 pEC50 >10000 nM EC50 Eur J Med Chem (2013) 65: 134-143 [PMID:23707918]
ChEMBL Inhibition of reverse transcriptase K103N mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 5.02 pEC50 9590 nM EC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Inhibition of reverse transcriptase Y188L mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 5.04 pEC50 9074 nM EC50 Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378]
ChEMBL Inhibition of HIV-1 p66/p51 reverse transcriptase Y181C mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis B 5.09 pEC50 8082 nM EC50 J Med Chem (2021) 64: 5067-5081 [PMID:33851529]
ChEMBL Inhibition of reverse transcriptase F227L/V106A double mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 5.09 pEC50 8041 nM EC50 Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378]
ChEMBL Inhibition of HIV-1 p66/p51 reverse transcriptase K103N mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis B 5.1 pEC50 8026 nM EC50 J Med Chem (2021) 64: 5067-5081 [PMID:33851529]
ChEMBL Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay F 5.12 pEC50 >7500 nM EC50 Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay F 5.12 pEC50 >7500 nM EC50 Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 5.19 pEC50 6496.4 nM EC50 Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537]
ChEMBL Inhibition of HIV1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 5.27 pEC50 5390 nM EC50 J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL Inhibition of reverse transcriptase Y188L mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 5.33 pEC50 4694 nM EC50 Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537]
ChEMBL Inhibition of HIV-1 p66/p51 reverse transcriptase L100I mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis B 5.39 pEC50 4106 nM EC50 J Med Chem (2021) 64: 5067-5081 [PMID:33851529]
ChEMBL Inhibition of reverse transcriptase K103N mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 5.41 pEC50 3922 nM EC50 Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378]
ChEMBL Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay F 5.41 pEC50 3900 nM EC50 Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL Inhibition of reverse transcriptase K103N mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 5.5 pEC50 3154.3 nM EC50 Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537]
ChEMBL Inhibition of HIV1 3B reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 5.68 pEC50 2100 nM EC50 J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL Inhibition of HIV-1 reverse transcriptase after 1 hr by spectrophotometry B 5.77 pEC50 1700 nM EC50 J Nat Prod (2013) 76: 2298-2306 [PMID:24308675]
ChEMBL Inhibition of reverse transcriptase L100I mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 5.92 pEC50 1201.7 nM EC50 Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537]
ChEMBL Inhibition of reverse transcriptase L100I mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 6.21 pEC50 622 nM EC50 Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378]
ChEMBL Inhibition of reverse transcriptase L100I mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 6.35 pEC50 450 nM EC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 8 in the article) B 6.42 pEC50 380 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Inhibition of HIV1 3B reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 6.57 pEC50 271 nM EC50 J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL Concentration required to inhibit HIV-1 reverse transcriptase activity (wild-type) by 50% B 6.6 pEC50 250 nM EC50 J Med Chem (2005) 48: 4378-4388 [PMID:15974590]
ChEMBL Inhibition of HIV-1 reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay B 6.62 pEC50 240 nM EC50 Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514]
ChEMBL Inhibition of reverse transcriptase E138K mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay B 6.77 pEC50 168 nM EC50 Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378]
ChEMBL Inhibition of wild-type HIV1 3B reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay B 6.91 pEC50 124 nM EC50 ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703]
ChEMBL Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 6 in the article) B 6.96 pEC50 110 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 12 in the article) B 7 pEC50 100 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Inhibition of reverse transcriptase E138K mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay B 7.12 pEC50 75 nM EC50 Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935]
ChEMBL Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 6 in the article) B 7.15 pEC50 70 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 7 in the article) B 7.28 pEC50 53 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay F 7.28 pEC50 52 nM EC50 Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 8 in the article) B 7.52 pEC50 30 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 7 in the article) B 7.59 pEC50 26 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 12 in the article) B 7.7 pEC50 20 nM EC50 Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403]
ChEMBL Inhibition of HIV1 reverse transcriptase by EIA B 8.44 pEC50 3.6 nM EC50 Bioorg Med Chem (2010) 18: 2029-2036 [PMID:20137956]
Human immunodeficiency virus type 2 pol protein in Human immunodeficiency virus 2 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5074] [UniProtKB: P88142]
ChEMBL Inhibitory activity against HIV rRT activity in HIV-2 B 4.7 pIC50 >20000 nM IC50 J Med Chem (1996) 39: 522-530 [PMID:8558522]
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human O positive erythrocyte assessed as reduction in parasitemia after 72 hrs F 4.19 pIC50 64000 nM IC50 Bioorg Med Chem (2014) 22: 5241-5248 [PMID:25199582]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]